• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    XtalPi Holdings (SEHK:2228) Just Gave The Market Something To Think About

    Simply Wall St·08/30/2026 04:25:00
    Listen to the news

    XtalPi Holdings (SEHK:2228) reported half year 2026 earnings with sales of CNY 393.63 million and a net loss of CNY 251.9 million, reversing from net income in the prior period.

    The latest half year results appear to have shifted sentiment around XtalPi Holdings, with the stock showing a 1 day share price return of 1.88% to HK$7.6 but a year to date share price return that is down 23.92% and a 1 year total shareholder return that is down 26.29%. Recent momentum has been mixed, with a 30 day share price return of 18.01% contrasted with weaker 90 day performance. This suggests the earnings swing back to a loss is still shaping how investors view the company’s risk and potential.

    Compare XtalPi Holdings with a hand picked 134 healthcare AI stocks that are also reacting to fresh earnings shifts and changing expectations.

    Given the swing back to a loss and the share price still down sharply over 12 months, it is worth asking how much of XtalPi Holdings recent move reflects the business itself rather than a reset in sentiment.

    Preferred Price-to-Sales Multiple of 41.3x: Is it justified?

    On the latest data, XtalPi Holdings trades on a P/S ratio of 41.3x, which puts a clear spotlight on how much investors are paying for each unit of current revenue at the last close of HK$7.60.

    The P/S ratio compares the company’s market value to its sales. For a research platform business like XtalPi Holdings that is still loss making, investors often look at sales as a core reference point because earnings are not yet a steady anchor.

    At 41.3x sales, the market is assigning a very rich tag to XtalPi Holdings revenue. That suggests expectations for strong execution on its AI for science and drug discovery platform. Simply Wall St also estimates a fair P/S ratio of 11.4x, which is materially lower and points to a level the market could move towards if enthusiasm cools or revenue does not keep pace with current hopes.

    Compared with the Asian Life Sciences industry average P/S of 5.1x and a peer average of 13.9x, XtalPi Holdings trades at a steep premium. This is not a small gap. It is a multiple of the sector norm and well above what similar companies trade on. This reinforces how much future growth is already reflected in the current price.

    Explore the SWS fair ratio for XtalPi Holdings.

    Result: Price-to-sales of 41.3x (OVERVALUED)

    However, XtalPi Holdings is still loss making and carries a very high P/S multiple, so any disappointment in platform adoption or key collaborations could quickly reset sentiment.

    Find out about the key risks to this XtalPi Holdings narrative.

    Another View on XtalPi Holdings Using the SWS DCF Model

    The P/S discussion paints XtalPi Holdings as very expensive, yet the SWS DCF model goes even further. On this view, the stock at HK$7.60 trades far above an estimated future cash flow value of HK$0.57, which implies a steep premium to the projected cash generation. For investors, the question is whether that gap reflects opportunity or valuation risk.

    Look into how the SWS DCF model arrives at its fair value.

    2228 Discounted Cash Flow as at Aug 2026
    2228 Discounted Cash Flow as at Aug 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out XtalPi Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 267 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    With sentiment around XtalPi Holdings pulling in different directions, it makes sense to move fast and test the numbers for yourself. To see what investors view as the company’s upside, review the 2 key rewards.

    Looking for more investment ideas beyond XtalPi Holdings?

    If you stop with XtalPi Holdings, you miss other stocks that might fit your goals even better. Broaden your options and test fresh ideas before the crowd moves.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.